Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1959 2
1961 3
1963 2
1964 3
1965 2
1966 2
1967 3
1968 1
1969 1
1970 2
1971 2
1975 2
1976 1
1978 2
1979 2
1980 2
1981 1
1982 5
1983 1
1984 1
1985 3
1986 2
1987 6
1988 2
1989 1
1990 6
1991 3
1992 4
1993 5
1994 3
1995 1
1996 1
1997 1
1998 2
2000 1
2001 2
2003 4
2004 2
2005 7
2006 2
2007 5
2008 5
2009 4
2010 4
2011 13
2012 15
2013 17
2014 14
2015 13
2016 11
2017 9
2018 28
2019 33
2020 43
2021 43
2022 28
2023 31
2024 39
2025 7

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

405 results

Results by year

Filters applied: . Clear all
Page 1
A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D.
Wedemeyer H, Aleman S, Brunetto MR, Blank A, Andreone P, Bogomolov P, Chulanov V, Mamonova N, Geyvandova N, Morozov V, Sagalova O, Stepanova T, Berger A, Manuilov D, Suri V, An Q, Da B, Flaherty J, Osinusi A, Liu Y, Merle U, Schulze Zur Wiesch J, Zeuzem S, Ciesek S, Cornberg M, Lampertico P; MYR 301 Study Group. Wedemeyer H, et al. Among authors: lampertico p. N Engl J Med. 2023 Jul 6;389(1):22-32. doi: 10.1056/NEJMoa2213429. Epub 2023 Jun 22. N Engl J Med. 2023. PMID: 37345876 Free article. Clinical Trial.
aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis.
Fan R, Papatheodoridis G, Sun J, Innes H, Toyoda H, Xie Q, Mo S, Sypsa V, Guha IN, Kumada T, Niu J, Dalekos G, Yasuda S, Barnes E, Lian J, Suri V, Idilman R, Barclay ST, Dou X, Berg T, Hayes PC, Flaherty JF, Zhou Y, Zhang Z, Buti M, Hutchinson SJ, Guo Y, Calleja JL, Lin L, Zhao L, Chen Y, Janssen HLA, Zhu C, Shi L, Tang X, Gaggar A, Wei L, Jia J, Irving WL, Johnson PJ, Lampertico P, Hou J. Fan R, et al. Among authors: lampertico p. J Hepatol. 2020 Dec;73(6):1368-1378. doi: 10.1016/j.jhep.2020.07.025. Epub 2020 Jul 21. J Hepatol. 2020. PMID: 32707225 Free article.
Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: Report from the 2022 AASLD-EASL HBV-HDV Treatment Endpoints Conference.
Ghany MG, Buti M, Lampertico P, Lee HM; 2022 AASLD-EASL HBV-HDV Treatment Endpoints Conference Faculty. Ghany MG, et al. Among authors: lampertico p. J Hepatol. 2023 Nov;79(5):1254-1269. doi: 10.1016/j.jhep.2023.06.002. Epub 2023 Jun 21. J Hepatol. 2023. PMID: 37377088 Review.
Hepatitis Delta: Ready for primetime?
Maasoumy B, Lampertico P. Maasoumy B, et al. Among authors: lampertico p. Liver Int. 2023 Aug;43 Suppl 1:1-4. doi: 10.1111/liv.15679. Liver Int. 2023. PMID: 37658668 No abstract available.
405 results